{
    "data": [
        {
            "id": "6904f7a5ecb8a70001462b38",
            "title": "REX&#39;s First Pure Play Drone ETF Takes Off",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">REX Shares has taken investors to new heights, literally, with the launch of the <strong>REX Drone ETF</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/DRNZ\" target=\"_blank\">DRNZ</a>), billed as the first <a href=\"https://www.benzinga.com/etfs\" target=\"_blank\">pure play fund</a> offering dedicated exposure to the global drone and unmanned aerial vehicle (UAV) economy.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>    • DRNZ stock is showing exceptional strength. <a href=\"https://www.benzinga.com/quote/DRNZ\" rel=\"noreferrer noopener\" target=\"_blank\">Review the technical setup here.</a></strong></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The new fund looks to capture both defense and commercial drone applications, giving investors a focused way to take part in one of the fastest-evolving technology frontiers. </p><!--/$--><!--$--><p class=\"block core-block\">Unlike traditional aerospace or defense ETFs, DRNZ zeroes in exclusively on the companies fueling the rise of drones across industries, from military reconnaissance and logistics to agriculture, infrastructure inspection and AI-enabled automation.</p><!--/$--><!--$--><p class=\"block core-block\">Tracking the <strong>VettaFi Drone Index</strong> (VDRONE), DRNZ follows global companies obtaining a significant portion of their revenue from drone-related businesses. The index's methodology favors \"pure play\" drone companies — those that derive at least 50% of their revenues from drones or related enabling technologies — while also allocating to diversified aerospace and defense firms with established UAV programs.</p><!--/$--><!--$--><div class=\"sc-gQfuga iaHpuj\"></div><!--/$--><!--$--><p class=\"block core-block\">The ETF comes with an expense ratio of 0.65% and looks to fully replicate the holdings within the index. At the end of October, the underlying index had heavy exposure to the industrial sector and Asian markets, underpinning the international nature of the drone ecosystem.</p><!--/$--><!--$--><p class=\"block core-block\">With increasing commercial use and government applications, industry projections have the global drone market more than doubling over the next decade. To investors, DRNZ offers a first-of-its-kind gateway into a market that is increasingly taking flight — both literally and figuratively.</p><!--/$--><!--$--><p class=\"block core-block\">The launch comes just over a month after Defiance <a href=\"https://www.benzinga.com/etfs/new-etfs/25/09/47894643/from-ai-to-delivery-drones-defiances-jedi-etf-targets-next-gen-autonomy\" target=\"_blank\">launched its own bet on drones and AI-driven autonomy</a> with the <strong>Defiance Drone &amp; Modern Warfare ETF</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/JEDI\" target=\"_blank\">JEDI</a>). Nonetheless, JEDI spreads out its exposure to the overall defense and modern-warfare market, which drones are a part of, while DRNZ is a pure play in drones.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">With this launch, REX continues to expand its suite of thematic and alternative ETFs. The issuer already manages products like the <strong>REX FANG &amp; Innovation Equity Premium Income ETF</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/FEPI\" target=\"_blank\">FEPI</a>), which has accrued over $550 million in assets.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48569459\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/etfs/new-etfs/25/10/48557596/franklin-templeton-bets-on-muni-market-momentum-with-5-new-tax-exempt-etfs\" target=\"_blank\">Franklin Templeton Bets On Muni Market Momentum With 5 New Tax-Exempt ETFs</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Barillo_Images via Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/Military-Kamikaze-Drones-With-Aerial-Bom.jpeg",
            "link": "https://www.benzinga.com/etfs/new-etfs/25/10/48569459/rexs-first-pure-play-drone-etf-takes-off",
            "pub_date": "2025-11-01 01:53:44",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6904e7b1ecb8a70001462282",
            "title": "Here&#39;s How Much You Would Have Made Owning Teledyne Technologies Stock In The Last 15 Years",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Teledyne Technologies (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/TDY\" target=\"_blank\">TDY</a>) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 18.3%. Currently, Teledyne Technologies has a market capitalization of $24.37 billion. </p><!--/$--><!--$--><p class=\"block core-block\"><strong>Buying $100 In TDY:</strong> If an investor had bought $100 of TDY stock 15 years ago, it would be worth <strong>$1,227.95</strong> today based on a price of $519.00 for TDY at the time of writing.</p><!--/$--><!--$--><h3 class=\"block core-block\">Teledyne Technologies's Performance Over Last 15 Years</h3><!--/$--><!--$--><div class=\"sc-feVKPA LhjAx core-image flex items-center justify-center\"><span style=\"background:none;border:0;box-sizing:border-box;display:inline-block;height:initial;margin:0;opacity:1;overflow:hidden;padding:0;width:initial;position:relative;max-width:100%\"><span style=\"background:none;border:0;box-sizing:border-box;display:block;height:initial;margin:0;opacity:1;padding:0;width:initial;max-width:100%\"><img alt=\"\" aria-hidden=\"true\" src=\"data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMTUwMCIgaGVpZ2h0PSI4MDAiIHhtbG5zPSJodHRwOi8vd3d3LnczLm9yZy8yMDAwL3N2ZyIgdmVyc2lvbj0iMS4xIi8+\" style=\"background:none;border:0;display:block;height:initial;margin:0;max-width:100%;opacity:1;padding:0;width:initial\"/></span><img alt=\"\" decoding=\"async\" loading=\"lazy\" src=\"data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/><noscript><img alt=\"\" decoding=\"async\" fetchpriority=\"low\" loading=\"lazy\" sizes=\"(max-width: 800px) 1500px, (min-width: 800px) 1500px\" src=\"https://www.benzinga.com/files/images/story/2025/1761929137_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840\" srcset=\"https://www.benzinga.com/files/images/story/2025/1761929137_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=1920 1x, https://www.benzinga.com/files/images/story/2025/1761929137_0.png?optimize=medium&amp;dpr=2&amp;auto=webp&amp;width=3840 2x\" style=\"border:none;bottom:0;box-sizing:border-box;display:block;height:0;left:0;margin:auto;max-height:100%;max-width:100%;min-height:100%;min-width:100%;padding:0;position:absolute;right:0;top:0;width:0;object-fit:contain\"/></noscript></span></div><!--/$--><!--$--><p class=\"block core-block\">Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p><!--/$--><!--$--><p class=\"block core-block\"><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--></div></div>",
            "image": "",
            "link": "https://www.benzinga.com/insights/news/25/10/48567308/heres-how-much-you-would-have-made-owning-teledyne-technologies-stock-in-the-last-15-years",
            "pub_date": "2025-11-01 00:45:41",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6904e98cecb8a70001462377",
            "title": "What&#39;s Going On With Bloom Energy Stock Today?",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Bloom Energy Corporation</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/BE\" target=\"_blank\">BE</a>) traded lower on Friday after unveiling a large private offering of zero-coupon <a href=\"https://www.benzinga.com/pressreleases/25/10/b48551071/bloom-energy-corporation-prices-upsized-2-2-billion-convertible-senior-notes-offering\" rel=\"noreferrer noopener\" target=\"_blank\">convertible notes due 2030.</a></p><!--/$--><!--$--><p class=\"block core-block\">The fuel cell maker priced $2.2 billion in total principal, up from $1.75 billion. Settlement is expected on November 4, 2025, pending<a href=\"https://www.benzinga.com/pressreleases/25/10/b48551071/bloom-energy-corporation-prices-upsized-2-2-billion-convertible-senior-notes-offering\" rel=\"noreferrer noopener\" target=\"_blank\"> standard closing conditions.</a></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Bloom Energy is issuing senior, unsecured notes maturing on November 15, 2030.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Also Read:<a href=\"https://www.benzinga.com/markets/tech/25/10/48553642/goldman-sachs-survey-finds-only-11-of-companies-cutting-jobs-as-ai-adoption-rises-report\" rel=\"noreferrer noopener\" target=\"_blank\"> Goldman Sachs Survey Finds Only 11% Of Companies Cutting Jobs As AI Adoption Rises: Report</a></strong></p><!--/$--><!--$--><p class=\"block core-block\">The securities carry no regular interest, and principal will not accrete. Noteholders may convert under certain conditions before August 15, 2030.</p><!--/$--><!--$--><p class=\"block core-block\">After that date, they may convert until shortly before maturity. Bloom Energy may settle conversions in cash, stock, or a mix.</p><!--/$--><!--$--><div class=\"sc-eQzVdq kfhAgV\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\"><strong>Use Of Proceeds</strong></h2><!--/$--><!--$--><p class=\"block core-block\">Bloom Energy estimates net proceeds of about $2.16 billion, or $2.45 billion if the option is fully exercised. About $988.4 million will fund cash consideration for concurrent exchanges of older convertible notes.</p><!--/$--><!--$--><p class=\"block core-block\">The company expects to exchange $532.8 million of 2028 notes for cash and about 24.3 million shares.</p><!--/$--><!--$--><p class=\"block core-block\">It will also swap $443.1 million of 2029 notes for cash and roughly 18.1 million shares.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">According to <a href=\"https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw\" rel=\"noreferrer noopener\" target=\"_blank\">Benzinga Pro</a>, BE stock has gained over 1,242% in the past year. Investors can gain exposure to the stock via<strong> the Global X Hydrogen</strong> ETF (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/HYDR\" target=\"_blank\">HYDR</a>).</p><!--/$--><!--$--><p class=\"block core-block\">Recently, the firm announced third-quarter revenue of $519.05 million, handily beating analyst estimates of $424.98 million and <a href=\"https://www.benzinga.com/markets/earnings/25/10/48479731/bloom-energy-q3-earnings-revenue-beat-eps-beat-shares-move-higher\" rel=\"noreferrer noopener\" target=\"_blank\">representing a 57.1% increase year-over-year.</a></p><!--/$--><!--$--><p class=\"block core-block\">Bloom also reported adjusted earnings of 15 cents per share, beating expectations of 9 cents per share.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">CEO <strong>KR Sridhar</strong> cited \"<a href=\"https://www.benzinga.com/markets/earnings/25/10/48479731/bloom-energy-q3-earnings-revenue-beat-eps-beat-shares-move-higher\" rel=\"noreferrer noopener\" target=\"_blank\">powerful tailwinds</a>\" for the strong performance, including surging electricity demand driven by artificial intelligence and key strategic partnerships with companies like Oracle <a href=\"https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48309073/bloom-energys-brookfield-deal-brings-prestige-not-profit-yet\" rel=\"noreferrer noopener\" target=\"_blank\">and Brookfield Asset Management.</a> The company ended the quarter with a strong cash position of approximately $595 million.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action:</strong> BE shares are trading higher by 0.41% to $128.62 at last check on Friday.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48567543\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/markets/equities/25/10/48557265/whats-going-on-with-trump-media-stock-today-3\" rel=\"noreferrer noopener\" target=\"_blank\">What’s Going On With Trump Media Stock Today?</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/Bloom-Energy.jpeg",
            "link": "https://www.benzinga.com/markets/equities/25/10/48567543/whats-going-on-with-bloom-energy-stock-today",
            "pub_date": "2025-11-01 00:53:35",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6904f402ecb8a70001462989",
            "title": "AutoNation Steps Up Capital Returns With New $1 Billion Buyback Plan",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>AutoNation Inc</strong>. (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/AN\" target=\"_blank\">AN</a>) said Friday its board authorized an <a href=\"https://www.benzinga.com/pressreleases/25/10/n48557235/autonation-board-authorizes-additional-1-billion-for-share-repurchase\" rel=\"noreferrer noopener\" target=\"_blank\">additional $1 billion repurchase</a> of the company’s common stock, extending its ongoing capital return program.</p><!--/$--><!--$--><p class=\"block core-block\">Following the new approval, AutoNation has about $1.28 billion remaining under its board-approved repurchase authorizations as of October 30.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The company has already repurchased 3 million shares this year for a total of $576 million, at an average price of $189 per share. As of October 30, AutoNation had roughly 36 million shares outstanding, down 8% from the end of 2024.</p><!--/$--><!--$--><p class=\"block core-block\"><strong><em>Also Read: <a href=\"https://www.benzinga.com/markets/equities/25/07/46633103/autonation-expands-financing-program-strengthening-its-cash-flow\" rel=\"noreferrer noopener\" target=\"_blank\">AutoNation Expands Financing Program, Strengthening Its Cash Flow</a></em></strong></p><!--/$--><!--$--><p class=\"block core-block\"><strong>Mike Manley</strong>, Chief Executive Officer of AutoNation, stated, “Our strong performance and consistent cash flow generation continue to support strategic investments in growth and shareholder returns.”</p><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><p class=\"block core-block\">“This additional $1 billion share repurchase authorization reflects our continued confidence in AutoNation’s performance and long-term strategy,” he added.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Third-Quarter Financial Results</h2><!--/$--><!--$--><p class=\"block core-block\">Last week, AutoNation reported its <a href=\"https://www.benzinga.com/markets/earnings/25/10/48386777/whats-going-on-with-autonation-stock-today\" rel=\"noreferrer noopener\" target=\"_blank\">third-quarter</a> adjusted earnings per share of $5.01 (plus 25% year over year), beating the analyst consensus estimate of $4.82.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\">Quarterly sales of $7.037 billion, outpacing the Street view of $6.86 billion. Revenues were up 7% driven by increases across all major categories.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Recent Acquisitions Expand Geographic and Brand Footprint</h2><!--/$--><!--$--><p class=\"block core-block\">In September, AutoNation acquired an Audi store and a Mercedes-Benz store in Chicago, following earlier purchases of a Mazda and a Ford store in Denver.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">Together, these deals exceed $500 million in annual revenue, broaden the brand mix, and deepen the company’s presence in Illinois and Colorado.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action</strong>: AN shares were trading higher by 1.85% to $199.35 at last check Friday.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48569042\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><em><a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48567091/another-monster-quarter-for-cloudflare-but-is-the-stock-getting-too-pricey\" rel=\"noreferrer noopener\" target=\"_blank\">Another Monster Quarter For Cloudflare, But Is the Stock Getting Too Pricey?</a></em></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by Piotr Swat via Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/Konskie--Poland---March-16--2024-Autonat.jpeg",
            "link": "https://www.benzinga.com/markets/buybacks/25/10/48569042/autonation-steps-up-capital-returns-with-new-1-billion-buyback-plan",
            "pub_date": "2025-11-01 01:38:13",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "6904f4b5ecb8a700014629d4",
            "title": "Gilead&#39;s HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Gilead Sciences Inc</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/GILD\" target=\"_blank\">GILD</a>) on Thursday reported adjusted earnings of $2.47 per share, beating <a href=\"https://www.benzinga.com/calendars/earnings\" rel=\"noreferrer noopener\" target=\"_blank\">the consensus of $2.13</a>.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><em>GILD is in positive territory. <a href=\"https://www.benzinga.com/quote/GILD\" rel=\"noreferrer noopener\" target=\"_blank\">Get the complete picture here</a></em></strong></li>\n</ul><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion.</p><!--/$--><!--$--><p class=\"block core-block\">Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell Therapy sales, partially offset by higher HIV and <a href=\"https://www.benzinga.com/pressreleases/25/10/b48543161/gilead-sciences-announces-third-quarter-2025-financial-results\" rel=\"noreferrer noopener\" target=\"_blank\">Livdelzi (seladelpar) sales</a>.</p><!--/$--><!--$--><p class=\"block core-block\">\"With multiple potential product launches in 2026, the strongest clinical pipeline in Gilead's history, and no major loss of exclusivity expected until 2036, we are well-positioned to drive positive impact for patients and continued growth of our business,\" said Daniel O'Day, Gilead's Chairman and CEO.</p><!--/$--><!--$--><p class=\"block core-block\">HIV product sales increased 4% to $5.3 billion. Liver Disease portfolio sales increased 12% to $819 million.</p><!--/$--><!--$--><p class=\"block core-block\">Biktarvy sales were up 6% to $3.7 billion. Descovy revenues jumped 20% to $701 million.</p><!--/$--><!--$--><div class=\"sc-ewfYpr ctXQJP\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Guidance</h2><!--/$--><!--$--><p class=\"block core-block\">Gilead raised its fiscal 2025 adjusted earnings guidance from $7.95 to $8.25 per share to $8.05 to $8.25, compared to the consensus of $8.03.</p><!--/$--><!--$--><p class=\"block core-block\">Gilead raised its sales guidance from $28.3 billion to $28.7 billion to $28.4 billion to $28.7 billion, exceeding the consensus of $28.84 billion.</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Analyst Take</h2><!--/$--><!--$--><p class=\"block core-block\"><strong>Needham</strong> reiterated its Buy rating for Gilead and maintained <a href=\"https://www.benzinga.com/quote/GILD/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">a $133 price forecast</a>.</p><!--/$--><!--$--><p class=\"block core-block\">Needham analyst Joseph Stringer says, \"We think upcoming readouts from the daily oral HIV treatment program (BIC/LEN) by YE25 and the anito-cel data in 4L+ r/r multiple myeloma could be key near-term catalysts for the stock.\"</p><!--/$--><!--$--><p class=\"block core-block\">Needham says HIV continues its standout performance. The cell therapy</p><!--/$--><!--$--><p class=\"block core-block\">franchise continued to underperform due to competitive headwinds, but Gilead remains dedicated to cell therapy.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">No notable macro elements such as drug pricing deals, as was seen with some large pharmas, and Gilead maintains an open dialogue \"across the administration.\"</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Cantor Fitzgerald</strong> reiterated its rating for Gilead with an Overweight and maintains a <a href=\"https://www.benzinga.com/quote/GILD/analyst-ratings\" rel=\"noreferrer noopener\" target=\"_blank\">price forecast of $135</a>.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>RBC Capital</strong> maintains a Sector Perform rating for Gilead and raises its price forecast from $100 to $105.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>GILD Price Action:</strong> Gilead Sciences shares were up 0.29% at $118.78 at the time of publication on Friday, <a href=\"https://www.benzinga.com/pro/\" rel=\"noreferrer noopener\" target=\"_blank\">according to Benzinga Pro data</a>.</p><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><em><a href=\"https://www.benzinga.com/markets/earnings/25/10/48555183/oil-gas-giant-chevron-clocks-record-oil-output-thanks-to-hess-acquisition\" rel=\"noreferrer noopener\" target=\"_blank\">Oil &amp; Gas Giant Chevron Clocks Record Oil Output Thanks To Hess Acquisition</a></em></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo by Michael Moloney via Shutterstock</em></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48569116\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/Boston--Massachusetts-July-7--2017--Hold.jpeg",
            "link": "https://www.benzinga.com/markets/earnings/25/10/48569116/gileads-hiv-drugs-power-earnings-beat-company-eyes-multiple-launches-by-2026",
            "pub_date": "2025-11-01 01:41:12",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}